Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder

Randomised, triple-blind, parallel-group trial testing repeated intravenous ketamine as augmentation for treatment-resistant major depressive disorder; participants received six infusions over three weeks (twice weekly).

Prior single-dose ketamine studies showed acute reductions in depression scores and suicidal ideation; this study evaluated feasibility and efficacy of repeated administration versus saline on depressive symptoms.